POFUT1 mRNA expression as an independent prognostic parameter in muscle-invasive bladder cancer.
FFPE tumor samples
Glycosyltransferases
Muscle-invasive bladder cancer
Prognostic marker
mRNA expression
qRT-PCR
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
22
04
2020
revised:
22
09
2020
accepted:
22
09
2020
pubmed:
26
10
2020
medline:
26
10
2020
entrez:
25
10
2020
Statut:
ppublish
Résumé
Muscle-invasive bladder cancer (MIBC) is characterized by high recurrence and rapid progression. Progression is linked to changes in glycan structures and altered levels of glycosyltransferases. The relationship of mRNA expression by glycosyltransferase genes B4GALT1, EXT1, MGAT5B, and POFUT1 to the probability of surviving MIBC after radical cystectomy has not yet been investigated. mRNA expression was analyzed using qRT-PCR in formalin-fixed and paraffin-embedded tumor samples (n = 105; 74% male patients and 26% female patients; median age = 72 years), correlated with histopathological variables, and evaluated by means of multivariable Cox regression analysis regarding to overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Multivariable Cox regression analysis identified POFUT1 mRNA expression as superior prognostic marker, compared with currently used histological tumor stage methods, for CSS by MIBC patients following radical cystectomy. Thus, the patients with low POFUT1 mRNA were at a 4.9-fold greater risk for cancer-specific death according to the multivariable analysis (p = 0.0001). Low mRNA levels predicted poor survival according to the Kaplan-Meier analysis ((POFUT1:OS p = 0.0014; CSS p = 0.0007; DFS p = 0.0088); (EXT1:OS p = 0.0150; CSS p = 0.0130; DFS p = 0.0286); (B4GALT1:CSS p = 0.0134; DFS p = 0.0493)). A subgroup analysis of patients without lymph node metastasis (pN-; n = 73) indicated that low expression of POFUT1 predicted reduced OS (p = 0.0073), CSS (p = 0.0058,) and DSS (p = 0.0079). Low levels of POFUT1 mRNA are an independent prognostic indicator for OS and CSS in MIBC patients following radical cystectomy. This finding demonstrates the importance of altered glycosylation for the progress of MIBC.
Identifiants
pubmed: 33099185
pii: S1936-5233(20)30392-2
doi: 10.1016/j.tranon.2020.100900
pmc: PMC7581975
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100900Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Glycobiology. 2015 Oct;25(10):1027-42
pubmed: 26175457
Urol Clin North Am. 1992 Nov;19(4):735-46
pubmed: 1279877
J Cancer Res Clin Oncol. 2018 Nov;144(11):2109-2115
pubmed: 30101373
Mol Oncol. 2013 Jun;7(3):719-31
pubmed: 23567325
BMC Cancer. 2014 Dec 02;14:901
pubmed: 25465919
BMC Cancer. 2018 May 24;18(1):590
pubmed: 29793447
Oncotarget. 2017 Apr 17;8(33):54506-54517
pubmed: 28903359
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3
pubmed: 12149519
Oncotarget. 2018 May 15;9(37):24684-24692
pubmed: 29872497
PLoS One. 2015 Nov 16;10(11):e0141253
pubmed: 26569621
Semin Urol Oncol. 1996 May;14(2):62-72
pubmed: 8734733
Analyst. 2010 Oct;135(10):2471-80
pubmed: 20714521
BMC Cancer. 2016 May 26;16:335
pubmed: 27229929
Immunol Rev. 2000 Feb;173:79-88
pubmed: 10719669
J Urol. 2006 Jan;175(1):90-3; discussion 93
pubmed: 16406879
Glycoconj J. 1998 Apr;15(4):323-31
pubmed: 9613818
Cancer Biol Med. 2015 Sep;12(3):246-54
pubmed: 26487969
Eur Urol. 2014 Aug;66(2):253-62
pubmed: 24472711
Oncol Lett. 2016 Nov;12(5):3845-3855
pubmed: 27895739
Nat Rev Urol. 2016 Aug;13(8):471-9
pubmed: 27431340
Biochem Biophys Res Commun. 2017 Sep 9;491(1):104-111
pubmed: 28709865
Cancer. 2002 Feb 1;94(3):673-85
pubmed: 11857299
Br J Cancer. 2017 Nov 7;117(10):1507-1517
pubmed: 28972965
Chem Rev. 1996 Mar 28;96(2):683-720
pubmed: 11848770
Int J Mol Sci. 2018 Oct 30;19(11):
pubmed: 30380731
BMC Med. 2013 Feb 07;11:31
pubmed: 23390961
Cancers (Basel). 2018 Oct 30;10(11):
pubmed: 30380753
Science. 2001 Mar 23;291(5512):2364-9
pubmed: 11269317
Curr Opin Struct Biol. 1996 Oct;6(5):679-91
pubmed: 8913692
Int J Oncol. 2013 Dec;43(6):1864-70
pubmed: 24064921
Oncotarget. 2018 Feb 19;9(19):15001-15014
pubmed: 29599921
Hum Mol Genet. 2004 Nov 15;13(22):2753-65
pubmed: 15385438
Transl Oncol. 2019 Apr;12(4):661-668
pubmed: 30831560
Glycobiology. 2002 Apr;12(4):43R-56R
pubmed: 12042244
Urol Oncol. 2017 Oct;35(10):606.e17-606.e23
pubmed: 28666720
Int J Cancer. 2020 Apr 1;146(7):1979-1992
pubmed: 31411736
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Oncotarget. 2016 Sep 27;7(39):63138-63157
pubmed: 27542232
Mol Oncol. 2017 Aug;11(8):895-912
pubmed: 28156048
Oncotarget. 2016 May 31;7(22):32723-30
pubmed: 27092876
Anticancer Res. 2003 Jul-Aug;23(4):3441-6
pubmed: 12926087
Nat Med. 2014 Oct;20(10):1199-205
pubmed: 25194568
Clin Cancer Res. 2006 Apr 15;12(8):2506-11
pubmed: 16638859
Biomol Eng. 2007 Jun;24(2):169-77
pubmed: 17419095
Pathology. 2014 Jun;46(4):274-82
pubmed: 24798156
Breast Cancer Res Treat. 2014 Jun;145(2):295-305
pubmed: 24737166
Urol Oncol. 2018 Dec;36(12):530.e19-530.e27
pubmed: 30446441
Mol Carcinog. 2001 Oct;32(2):61-72
pubmed: 11746818